Vaccine

Maravai LifeSciences Hosts 2023 Investor R&D Day

Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlookSAN DIEGO, Sept. 29, 2023 (GLOBE…

2 years ago

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

2 years ago

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

2 years ago

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

2 years ago

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…

2 years ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX…

2 years ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to…

2 years ago

Tonix Pharmaceuticals Announces Proposed Public Offering

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

2 years ago

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS

New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome…

2 years ago

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Positive Conclusion Reached in Immunomodulator I Patent OppositionPatent opposition hearing cancelledLONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg…

2 years ago